Profesor Invitado: Dr. José Ricardo Correa Rotter
Especialista en Nefrología
Profesor Invitado: Dr. Juan Carlos Arreola Guerra
Especialista en Nefrología
Objetivo de Aprendizaje:
- Conocer las nuevas alternativas terapéuticas para el control del potasio, incluyendo su mecanismo de acción y perfil de seguridad en el uso crónico.
- Comprender el impacto de los nuevos quelantes de potasio en la continuidad y optimización de terapias cardio-renales como iSRAA en pacientes con ERC e insuficiencia cardiaca.
- Reconocer las ventajas clínicas de estas terapias, como su inicio de acción rápido, acción localizada y eficacia sostenida en el manejo preventivo de la hipercalemia.
Referencias:
- Collins AJ, et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol. 2017;46(3):213-221.
- Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014 Nov;10(11):653-62.
- Vardeny O, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014 Jul;7(4):573-9.
- Xu H, et al. Prevalence of hyperkalemia in DOPPS: a real-world, international cohort of hemodialysis patients. Poster presented at: European Renal Association–European Dialysis and Transplant Association (ERA–EDTA) 54th Annual Congress; 2017 Jun 3–6; Madrid, Spain. DOI: 10.3252/pso.eu.54ERA.2017.
- Bem D, et al. The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review. Ren Fail. 2021 Dec;43(1):241-254.
- Nilsson E, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017 Oct 15:245:277-284.
- Chomicki J, et al. Evaluation of the incidence of hyperkalemia in patients prescribed spironolactone for the treatment of resistant hypertension. J Am Soc Hypertens. 2014;8(4S):e30. Abs. P-10.
- Khosla N, et al. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30(5):418-24.
- Thomsen RW, et al. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. Nephrol Dial Transplant. 2018 Sep 1;33(9):1610-1620.
- Thomsen RW, et al. Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study. J Am Heart Assoc. 2018 May 22;7(11):e008912.
- Epstein M, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015 Sep;21(11 Suppl):S212-20.
- Zannad FG, et al. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail. 2020 Feb;7(1):54-64.
- Stavros F, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014 Dec 22;9(12):e114686.
- Dunn JD, et al. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015;21(15 Suppl):bs307–s315.